A new approach to identifying “signposts” on cancer cells may help immune cells eliminate the disease
With new immunotherapy treatments for melanoma, recovery rates have risen dramatically, in some cases to around 50%. But they could be much higher: A new study led by researchers at the Weizmann Institute of Science showed, in lab dishes and animal studies, that a highly personalized approach could help the immune cells improve their abilities to recognize the cancer and kill it. The results of this study were published today in Cancer Discovery.
Today’s immunotherapies involve administering antibodies to unlock the natural immune T cells that recognize and kill cancer cells; or else growing and reactivating these T cells outside the body and returning them in a ‘weaponized’ form. “But none of this will kill the cancer if the immune cells do not recognize the ‘signposts’ that mark cancer cells as foreign,” says Prof. Yardena Samuels of the Institute’s Molecular Cell Biology Department.
Groups around the world are searching for such signposts – mutated peptides known as neo-antigens on the cancer cells’ outer membranes. Identifying the particular peptides that present themselves to the T cell can then help develop personalized cancer vaccines based on neo-antigen profiles. One of the problems in uncovering neo-antigens in cancers like melanoma, however, is that they are presented by a protein complex called HLA – a complex that can come in thousands of versions, even without the addition of cancerous mutations. Indeed, the algorithms that are often used to search the cancer-cell genome for possible neo-antigens had predicted hundreds of possible candidates.
Fewer neo-antigens, better results
Samuels, together with her PhD student Shelly Kalaora and in collaboration with Prof Arie Admon of the Technion – Israel Institute of Technology, bypassed the algorithm methods. They used a method Admon had developed to remove the peptides from the melanoma cells’ HLA complex and investigate their interactions with T cells. Says Samuels: “We discovered that tumors present many fewer neo-antigens than we expected. Our neo-antigen and corresponding T-cell-identification strategies were so robust, our neo-antigen-specific T cells killed 90% of their target melanoma cells both on plates and in mice. This suggests possible clinical applications for the near future. Some of the peptides we identified are neo-antigens that had not even shown up in the algorithm studies; in other words, the method we used, called HLA peptidomics, is really complementary to these methods.
Samuels and Kalaora worked with a team that included Dr. Eytan Ruppin of the National Cancer Institute, USA; Dr. Jennifer Wargo of the University of Texas MD Anderson Cancer Center, Houston, and Prof. Nir Friedman of the Weizmann Institute of Science’s Molecular Cell Biology Department.
Neo-antigen-specific T cells killed 90% of their target melanoma cells
For some of the patients the group had obtained multiple samples, and this enabled them to ask questions about metastasis – for example, whether the same neo-antigens were present on secondary tumors after the cancer had spread to other organs. “This is the first time that HLA peptide studies of multiple metastases derived from the same patient have ever been performed. The significant similarity between the various HLA-peptidomes has strong implications for the process of choosing neo-antigens for patient treatment, showing that it is clearly essential not only to identify the immunogenic peptides presented on the cancer cells, but to select the ones that are common to the patient’s metastases. This can then help direct systemic therapeutic responses in patients with multiple metastases,” says Kalaora.
A new drug for every patient
And then the group took their findings one step further: Using natural T cells extracted from 14 of the patients, the researchers identified those that most strongly react with the neo-antigens. They sequenced the genomes of these cells, grew them and tested them in animal models with the patients’ tumor cells. In both lab dish experiments and mice, they showed that the response of the T cells they identified was highly effective in fighting the cancer.
Samuels points out that “although this research is experimental right now, the findings are highly relevant to clinical research, as groups around the world have already worked out the basics of developing therapeutic anti-cancer treatments based on neo-antigens. As almost all the neo-antigens detected in patients thus far are individual – and unique to the particular cancerous tissue – they constitute an ideal class of anti-cancer targets. This would be the ultimate “personalized” cancer therapy – a new drug is created for every patient.”
The Latest on: Neo-antigens
via Google News
The Latest on: Neo-antigens
- Comprehensive review of targeted therapy for colorectal canceron March 19, 2020 at 4:06 pm
Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and chemotherapy have long been ...
- Chi Lin, MD, PhD, on Immunotherapy and Chemoradiation in Pancreatic Canceron March 19, 2020 at 1:24 pm
Combining immunotherapy with neoadjuvant chemotherapy and/or chemoradiation therapy could further enhance the conversion of borderline resectable tumor to resectable tumor because chemotherapy and ...
- Chi Lin, MD, PhD, on Immunotherapy and Chemoradiation in Pancreatic Canceron March 19, 2020 at 1:22 pm
This promotes the presentation of the neoantigens in the tumor microenvironment, thereby increasing the immunogenicity of the tumor cells making them better targets for immunotherapy. The ...
- A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal canceron March 18, 2020 at 11:44 am
These authors contributed equally to this work. See allHide authors and affiliations Neoantigen vaccines have been enthusiastically pursued for personalized cancer immunotherapy while vast majority of ...
- VAXIL CHANGES WEBSITE DOMAIN NAME, PROVIDES UPDATE ON THE EXERCISE OF WARRANTS AND RECEIVES FINAL TSXV EXCHANGE APPROVAL ON THE DEBENTURE FINANCINGSon March 18, 2020 at 6:10 am
VAXIL BIO LTD. (“ Vaxil ” or the “ Company ”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, announces that it has moved its website to ...
- Mateon to Develop its OT-101, a Phase 3 Clinical Drug Candidate, Initially Against COVID-19on March 18, 2020 at 5:00 am
OT-101- a TGF-B2 inhibitor - has demonstrated potent antiviral activity against coronavirus OT-101 - an RNA therapeutic - is part of the Company's proprietary platform for rapid antiviral response ...
- Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officeron March 17, 2020 at 5:00 am
Professor Quezada is an internationally recognized leader in the field of cancer immunology and a founder of the company - Stevenage, UK 17 March 2020 – Achilles Therapeutics (“Achilles”), a ...
- Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officeron March 17, 2020 at 12:06 am
In 2016 he co-led ground-breaking research supporting the key role of clonal tumour neoantigens in the immune response to cancer; research that underpins the Achilles approach. Professor Quezada ...
- Sesen Bio's (SESN) CEO Thomas Cannell on Q4 2019 Results - Earnings Call Transcripton March 16, 2020 at 8:50 am
But even more interesting is what we believe occurs with the second mechanism. Because Vicinium causes immunogenic cell death, it appears that DAMPs and neoantigens are released. This results in T ...
via Bing News